Chinese General Practice ›› 2023, Vol. 26 ›› Issue (26): 3252-3258.DOI: 10.12114/j.issn.1007-9572.2023.0103
• Original Research·Monographic Research·Type 2 Diabetic • Previous Articles Next Articles
Received:
2022-12-02
Revised:
2023-03-25
Published:
2023-09-15
Online:
2023-04-25
Contact:
MA Huijuan
通讯作者:
马慧娟
作者简介:
基金资助:
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.chinagp.net/EN/10.12114/j.issn.1007-9572.2023.0103
组别 | 例数 | 年龄〔M(P25,P75),岁〕 | 性别(男/女) | 病程〔M(P25,P75),年〕 | BMI〔M(P25,P75),kg/m2〕 | 吸烟〔例(%)〕 | 饮酒〔例(%)〕 | 高血压〔例(%)〕 | FBG〔M(P25,P75),mmol/L〕 |
---|---|---|---|---|---|---|---|---|---|
合并MAFLD组 | 734 | 56(46,66) | 458/276 | 7(2,15) | 26.8(25.1,29.3) | 242(33.0) | 210(28.8) | 404(55.0) | 8.64(6.65,11.43) |
未合并MAFLD组 | 700 | 62(53,71) | 397/303 | 10(4,18) | 24.2(21.9,26.3) | 189(27.0) | 140(20.0) | 340(48.6) | 7.88(6.14,11.02) |
Z(χ2)值 | -7.39 | 4.67a | -5.79 | -16.11 | 5.57a | 13.59a | 6.01a | -3.22 | |
P值 | <0.001 | 0.310 | <0.001 | <0.001 | 0.018 | <0.001 | 0.014 | 0.001 | |
组别 | HbA1c〔M(P25,P75),%〕 | UA〔M(P25,P75),μmol/L〕 | Scr〔M(P25,P75),μmol/L〕 | TC〔M(P25,P75),mmol/L〕 | TG〔M(P25,P75),mmol/L〕 | HDL-C〔M(P25,P75),mmol/L〕 | LDL-C〔M(P25,P75),mmol/L〕 | ||
合并MAFLD组 | 8.70(7.50,10.48) | 317.30(261.50,380.30) | 72.40(64.50,82.70) | 4.88(4.01,5.63) | 1.75(1.23,2.64) | 0.98(0.85,1.17) | 3.14(2.57,3.70) | ||
未合并MAFLD组 | 8.50(7.10,10.60) | 288.10(228.60,341.65) | 71.20(62.90,81.70) | 4.49(3.77,5.30) | 1.18(0.87,1.73) | 1.06(0.89,1.26) | 2.91(2.32,3.50) | ||
Z(χ2)值 | -1.89 | -6.79 | -1.15 | -4.49 | -11.98 | -4.91 | -4.37 | ||
P值 | 0.590 | <0.001 | 0.249 | <0.001 | <0.001 | <0.001 | <0.001 | ||
组别 | AST〔M(P25,P75),U/L〕 | ALT〔M(P25,P75),U/L〕 | GGT〔M(P25,P75),U/L〕 | BA〔M(P25,P75),μmol/L〕 | ALB〔M(P25,P75),g/L〕 | eGDR〔M(P25,P75)〕 | |||
合并MAFLD组 | 19.90(16.15,26.15) | 20.80(14.95,33.70) | 28.80(19.53,44.88) | 3.06(2.06,4.82) | 41.40(38.52,43.80) | 5.50(4.12,7.30) | |||
未合并MAFLD组 | 18.10(14.60,22.50) | 15.80(11.85,22.25) | 21.00(14.73,30.38) | 2.94(1.83,4.90) | 39.30(36.68,42.60) | 6.51(5.12,8.22) | |||
Z(χ2)值 | -5.49 | -9.61 | -9.63 | -0.84 | -7.80 | -7.63 | |||
P值 | <0.001 | <0.001 | <0.001 | 0.401 | <0.001 | <0.001 |
Table 1 Comparison of baseline data between patients with and without MAFLD
组别 | 例数 | 年龄〔M(P25,P75),岁〕 | 性别(男/女) | 病程〔M(P25,P75),年〕 | BMI〔M(P25,P75),kg/m2〕 | 吸烟〔例(%)〕 | 饮酒〔例(%)〕 | 高血压〔例(%)〕 | FBG〔M(P25,P75),mmol/L〕 |
---|---|---|---|---|---|---|---|---|---|
合并MAFLD组 | 734 | 56(46,66) | 458/276 | 7(2,15) | 26.8(25.1,29.3) | 242(33.0) | 210(28.8) | 404(55.0) | 8.64(6.65,11.43) |
未合并MAFLD组 | 700 | 62(53,71) | 397/303 | 10(4,18) | 24.2(21.9,26.3) | 189(27.0) | 140(20.0) | 340(48.6) | 7.88(6.14,11.02) |
Z(χ2)值 | -7.39 | 4.67a | -5.79 | -16.11 | 5.57a | 13.59a | 6.01a | -3.22 | |
P值 | <0.001 | 0.310 | <0.001 | <0.001 | 0.018 | <0.001 | 0.014 | 0.001 | |
组别 | HbA1c〔M(P25,P75),%〕 | UA〔M(P25,P75),μmol/L〕 | Scr〔M(P25,P75),μmol/L〕 | TC〔M(P25,P75),mmol/L〕 | TG〔M(P25,P75),mmol/L〕 | HDL-C〔M(P25,P75),mmol/L〕 | LDL-C〔M(P25,P75),mmol/L〕 | ||
合并MAFLD组 | 8.70(7.50,10.48) | 317.30(261.50,380.30) | 72.40(64.50,82.70) | 4.88(4.01,5.63) | 1.75(1.23,2.64) | 0.98(0.85,1.17) | 3.14(2.57,3.70) | ||
未合并MAFLD组 | 8.50(7.10,10.60) | 288.10(228.60,341.65) | 71.20(62.90,81.70) | 4.49(3.77,5.30) | 1.18(0.87,1.73) | 1.06(0.89,1.26) | 2.91(2.32,3.50) | ||
Z(χ2)值 | -1.89 | -6.79 | -1.15 | -4.49 | -11.98 | -4.91 | -4.37 | ||
P值 | 0.590 | <0.001 | 0.249 | <0.001 | <0.001 | <0.001 | <0.001 | ||
组别 | AST〔M(P25,P75),U/L〕 | ALT〔M(P25,P75),U/L〕 | GGT〔M(P25,P75),U/L〕 | BA〔M(P25,P75),μmol/L〕 | ALB〔M(P25,P75),g/L〕 | eGDR〔M(P25,P75)〕 | |||
合并MAFLD组 | 19.90(16.15,26.15) | 20.80(14.95,33.70) | 28.80(19.53,44.88) | 3.06(2.06,4.82) | 41.40(38.52,43.80) | 5.50(4.12,7.30) | |||
未合并MAFLD组 | 18.10(14.60,22.50) | 15.80(11.85,22.25) | 21.00(14.73,30.38) | 2.94(1.83,4.90) | 39.30(36.68,42.60) | 6.51(5.12,8.22) | |||
Z(χ2)值 | -5.49 | -9.61 | -9.63 | -0.84 | -7.80 | -7.63 | |||
P值 | <0.001 | <0.001 | <0.001 | 0.401 | <0.001 | <0.001 |
组别 | 例数 | 年龄〔M(P25,P75),岁〕 | 性别(男/女) | 病程〔M(P25,P75),年〕 | 合并MAFLD〔例(%)〕 | BMI〔M(P25,P75),kg/m2〕 | 吸烟〔例(%)〕 | 饮酒〔例(%)〕 | 高血压〔例(%)〕 |
---|---|---|---|---|---|---|---|---|---|
T1组 | 477 | 60(49,69) | 272/205 | 10(3,18) | 311(65.1) | 27.3(25.4,30.2) | 165(34.5) | 108(22.7) | 429(89.9) |
T2组 | 478 | 60(49,70) | 298/180 | 9(3,15) | 233(48.9) | 25.3(23.4,27.0)a | 171(35.8) | 137(28.8) | 288(60.3) |
T3组 | 479 | 55(47,64)ab | 303/176 | 8(3,14) | 202(42.2) | 24.2(22.2,26.5)ab | 146(30.8) | 116(24.5) | 23(4.8) |
H(χ2)值 | 20.36 | 4.27c | 2.68 | 48.26c | 213.15 | 2.52c | 4.17c | 648.66c | |
P值 | <0.001 | 0.118 | 0.262 | <0.001 | <0.001 | 0.286 | 0.125 | <0.001 | |
组别 | FBG〔M(P25,P75),mmol/L〕 | HbA1c〔M(P25,P75),%〕 | UA〔M(P25,P75),μmol/L〕 | Scr〔M(P25,P75),μmol/L〕 | TC〔M(P25,P75),mmol/L〕 | TG〔M(P25,P75),mmol/L〕 | |||
T1组 | 9.70(7.17,12.21) | 9.80(8.60,11.20) | 314.35(249.15,382.38) | 73.25(64.70,85.43) | 4.73(3.89,5.67) | 1.65(1.13,2.46) | |||
T2组 | 7.94(6.12,11.44)a | 8.20(6.90,11.00)a | 303.30(246.10,365.60) | 73.20(64.50,83.15) | 4.69(3.89,5.52) | 1.41(1.03,2.25)a | |||
T3组 | 7.57(6.17,9.57)ab | 7.90(6.70,9.10)ab | 291.10(237.13,343.95)a | 69.60(61.98,77.78)ab | 4.69(3.96,5.43) | 1.38(0.88,2.03)ab | |||
H(χ2)值 | 59.51 | 210.07 | 12.72 | 24.38 | 0.39 | 28.99 | |||
P值 | <0.001 | <0.001 | 0.002 | <0.001 | 0.823 | <0.001 | |||
组别 | HDL-C〔M(P25,P75),mmol/L〕 | LDL-C〔M(P25,P75),mmol/L〕 | AST〔M(P25,P75),U/L〕 | ALT〔M(P25,P75),U/L〕 | GGT〔M(P25,P75),U/L〕 | BA〔M(P25,P75),μmol/L〕 | ALB〔M(P25,P75),g/L〕 | ||
T1组 | 0.98(0.84,1.17) | 3.05(2.46,3.71) | 19.00(15.30,24.10) | 18.70(13.65,28.85) | 25.90(18.45,41.10) | 3.08(2.02,4.85) | 40.10(37.40,42.70) | ||
T2组 | 1.02(0.86,1.21) | 3.06(2.47,3.64) | 19.30(15.63,23.60) | 17.85(13.50,26.00) | 24.60(17.70,37.48) | 2.97(1.92,4.95) | 40.90(37.60,43.10) | ||
T3组 | 1.07(0.91,1.25)ab | 3.00(2.49,3.58) | 19.00(15.60,24.48) | 18.45(13.33,26.88) | 23.15(15.98,35.88)a | 3.00(1.90,4.80) | 41.10(38.70,43.90)ab | ||
H(χ2)值 | 19.98 | 0.40 | 0.39 | 2.79 | 7.39 | 0.08 | 21.57 | ||
P值 | <0.001 | 0.819 | 0.823 | 0.248 | 0.025 | 0.961 | <0.001 |
Table 2 Comparison of baseline data of subjects among groups with different eGDR levels
组别 | 例数 | 年龄〔M(P25,P75),岁〕 | 性别(男/女) | 病程〔M(P25,P75),年〕 | 合并MAFLD〔例(%)〕 | BMI〔M(P25,P75),kg/m2〕 | 吸烟〔例(%)〕 | 饮酒〔例(%)〕 | 高血压〔例(%)〕 |
---|---|---|---|---|---|---|---|---|---|
T1组 | 477 | 60(49,69) | 272/205 | 10(3,18) | 311(65.1) | 27.3(25.4,30.2) | 165(34.5) | 108(22.7) | 429(89.9) |
T2组 | 478 | 60(49,70) | 298/180 | 9(3,15) | 233(48.9) | 25.3(23.4,27.0)a | 171(35.8) | 137(28.8) | 288(60.3) |
T3组 | 479 | 55(47,64)ab | 303/176 | 8(3,14) | 202(42.2) | 24.2(22.2,26.5)ab | 146(30.8) | 116(24.5) | 23(4.8) |
H(χ2)值 | 20.36 | 4.27c | 2.68 | 48.26c | 213.15 | 2.52c | 4.17c | 648.66c | |
P值 | <0.001 | 0.118 | 0.262 | <0.001 | <0.001 | 0.286 | 0.125 | <0.001 | |
组别 | FBG〔M(P25,P75),mmol/L〕 | HbA1c〔M(P25,P75),%〕 | UA〔M(P25,P75),μmol/L〕 | Scr〔M(P25,P75),μmol/L〕 | TC〔M(P25,P75),mmol/L〕 | TG〔M(P25,P75),mmol/L〕 | |||
T1组 | 9.70(7.17,12.21) | 9.80(8.60,11.20) | 314.35(249.15,382.38) | 73.25(64.70,85.43) | 4.73(3.89,5.67) | 1.65(1.13,2.46) | |||
T2组 | 7.94(6.12,11.44)a | 8.20(6.90,11.00)a | 303.30(246.10,365.60) | 73.20(64.50,83.15) | 4.69(3.89,5.52) | 1.41(1.03,2.25)a | |||
T3组 | 7.57(6.17,9.57)ab | 7.90(6.70,9.10)ab | 291.10(237.13,343.95)a | 69.60(61.98,77.78)ab | 4.69(3.96,5.43) | 1.38(0.88,2.03)ab | |||
H(χ2)值 | 59.51 | 210.07 | 12.72 | 24.38 | 0.39 | 28.99 | |||
P值 | <0.001 | <0.001 | 0.002 | <0.001 | 0.823 | <0.001 | |||
组别 | HDL-C〔M(P25,P75),mmol/L〕 | LDL-C〔M(P25,P75),mmol/L〕 | AST〔M(P25,P75),U/L〕 | ALT〔M(P25,P75),U/L〕 | GGT〔M(P25,P75),U/L〕 | BA〔M(P25,P75),μmol/L〕 | ALB〔M(P25,P75),g/L〕 | ||
T1组 | 0.98(0.84,1.17) | 3.05(2.46,3.71) | 19.00(15.30,24.10) | 18.70(13.65,28.85) | 25.90(18.45,41.10) | 3.08(2.02,4.85) | 40.10(37.40,42.70) | ||
T2组 | 1.02(0.86,1.21) | 3.06(2.47,3.64) | 19.30(15.63,23.60) | 17.85(13.50,26.00) | 24.60(17.70,37.48) | 2.97(1.92,4.95) | 40.90(37.60,43.10) | ||
T3组 | 1.07(0.91,1.25)ab | 3.00(2.49,3.58) | 19.00(15.60,24.48) | 18.45(13.33,26.88) | 23.15(15.98,35.88)a | 3.00(1.90,4.80) | 41.10(38.70,43.90)ab | ||
H(χ2)值 | 19.98 | 0.40 | 0.39 | 2.79 | 7.39 | 0.08 | 21.57 | ||
P值 | <0.001 | 0.819 | 0.823 | 0.248 | 0.025 | 0.961 | <0.001 |
项目 | 合并MAFLD组 | 未合并MAFLD组 | 项目 | 合并MAFLD组 | 未合并MAFLD组 |
---|---|---|---|---|---|
年龄 | -0.096a | -0.159a | HDL-C | 0.068 | 0.194a |
病程 | -0.004 | -0.119a | LDL-C | -0.019 | 0.012 |
FBG | -0.224a | -0.250a | AST | -0.038 | 0.117a |
UA | -0.065 | -0.027 | ALT | -0.032 | 0.053 |
Scr | -0.056 | -0.145a | GGT | -0.044 | 0.080a |
TC | -0.017 | 0.039 | BA | -0.051 | 0.028 |
TG | -0.064 | -0.179a | ALB | -0.188a | -0.236a |
Table 3 Correlation analysis between eGDR and baseline data
项目 | 合并MAFLD组 | 未合并MAFLD组 | 项目 | 合并MAFLD组 | 未合并MAFLD组 |
---|---|---|---|---|---|
年龄 | -0.096a | -0.159a | HDL-C | 0.068 | 0.194a |
病程 | -0.004 | -0.119a | LDL-C | -0.019 | 0.012 |
FBG | -0.224a | -0.250a | AST | -0.038 | 0.117a |
UA | -0.065 | -0.027 | ALT | -0.032 | 0.053 |
Scr | -0.056 | -0.145a | GGT | -0.044 | 0.080a |
TC | -0.017 | 0.039 | BA | -0.051 | 0.028 |
TG | -0.064 | -0.179a | ALB | -0.188a | -0.236a |
变量 | β | SE | Wald χ2值 | OR(95%CI) | P值 |
---|---|---|---|---|---|
年龄 | -0.026 | 0.004 | 50.038 | 0.974(0.967,0.981) | <0.001 |
性别 | -0.233 | 0.108 | 4.664 | 0.792(0.641,0.979) | 0.031 |
病程 | <0.001 | <0.001 | 0.401 | 1.000(0.999,1.001) | 0.527 |
吸烟 | 0.278 | 0.118 | 5.553 | 1.320(1.048,1.663) | 0.018 |
饮酒 | 0.477 | 0.130 | 13.469 | 1.611(1.249,2.078) | <0.001 |
FBG | <0.001 | <0.001 | 0.404 | 1.000(0.999,1.001) | 0.525 |
UA | 0.004 | 0.001 | 42.755 | 1.004(1.003,1.005) | <0.001 |
TC | -0.001 | 0.010 | 0.006 | 0.999(0.980,1.019) | 0.941 |
TG | 0.073 | 0.026 | 7.506 | 1.075(1.021,1.132) | 0.006 |
HDL-C | -0.608 | 0.187 | 10.537 | 0.545(0.377,0.786) | 0.001 |
LDL-C | 0.194 | 0.059 | 10.858 | 1.214(1.082,1.362) | 0.001 |
AST. | 0.021 | 0.005 | 18.338 | 1.021(1.011,1.030) | <0.001 |
ALT | 0.028 | 0.004 | 47.739 | 1.029(1.020,1.037) | <0.001 |
GGT | 0.005 | 0.001 | 11.730 | 1.005(1.002,1.008) | 0.001 |
BA | -0.021 | 0.010 | 4.241 | 0.979(0.959,0.999) | 0.039 |
ALB | 0.106 | 0.013 | 62.552 | 1.112(1.083,1.142) | <0.001 |
eGDR | -0.206 | 0.027 | 59.131 | 0.814(0.772,0.858) | <0.001 |
Table 4 Univariate Logistic regression analysis of influencing factors for MAFLD in T2DM patients
变量 | β | SE | Wald χ2值 | OR(95%CI) | P值 |
---|---|---|---|---|---|
年龄 | -0.026 | 0.004 | 50.038 | 0.974(0.967,0.981) | <0.001 |
性别 | -0.233 | 0.108 | 4.664 | 0.792(0.641,0.979) | 0.031 |
病程 | <0.001 | <0.001 | 0.401 | 1.000(0.999,1.001) | 0.527 |
吸烟 | 0.278 | 0.118 | 5.553 | 1.320(1.048,1.663) | 0.018 |
饮酒 | 0.477 | 0.130 | 13.469 | 1.611(1.249,2.078) | <0.001 |
FBG | <0.001 | <0.001 | 0.404 | 1.000(0.999,1.001) | 0.525 |
UA | 0.004 | 0.001 | 42.755 | 1.004(1.003,1.005) | <0.001 |
TC | -0.001 | 0.010 | 0.006 | 0.999(0.980,1.019) | 0.941 |
TG | 0.073 | 0.026 | 7.506 | 1.075(1.021,1.132) | 0.006 |
HDL-C | -0.608 | 0.187 | 10.537 | 0.545(0.377,0.786) | 0.001 |
LDL-C | 0.194 | 0.059 | 10.858 | 1.214(1.082,1.362) | 0.001 |
AST. | 0.021 | 0.005 | 18.338 | 1.021(1.011,1.030) | <0.001 |
ALT | 0.028 | 0.004 | 47.739 | 1.029(1.020,1.037) | <0.001 |
GGT | 0.005 | 0.001 | 11.730 | 1.005(1.002,1.008) | 0.001 |
BA | -0.021 | 0.010 | 4.241 | 0.979(0.959,0.999) | 0.039 |
ALB | 0.106 | 0.013 | 62.552 | 1.112(1.083,1.142) | <0.001 |
eGDR | -0.206 | 0.027 | 59.131 | 0.814(0.772,0.858) | <0.001 |
变量 | 模型1 | 模型2 | 模型3 | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
β | SE | Wald χ2值 | OR(95%CI) | P值 | β | SE | Wald χ2值 | OR(95%CI) | P值 | β | SE | Wald χ2值 | OR(95%CI) | P值 | |
eGDR | -0.247 | 0.033 | 54.322 | 0.781(0.732,0.834) | <0.001 | -0.244 | 0.032 | 60.129 | 0.783(0.736,0.833) | <0.001 | -0.206 | 0.027 | 59.131 | 0.814(0.772,0.858) | <0.001 |
eGDR分组(以T3组为参照) | |||||||||||||||
T1组 | 0.351 | 0.158 | 4.957 | 1.420(1.043,1.934) | 0.026 | 0.381 | 0.151 | 6.328 | 1.464(1.088,1.969) | 0.012 | 0.270 | 0.136 | 3.916 | 1.31(1.003,1.712) | 0.048 |
T2组 | 1.076 | 0.169 | 40.448 | 2.934(2.106,4.089) | <0.001 | 1.090 | 0.160 | 46.324 | 2.973(2.172,4.068) | <0.001 | 0.938 | 0.14 | 44.935 | 2.554(1.941,3.359) | <0.001 |
Table 5 Multivariate Logistic regression analysis of eGDR and its grouping for T2DM with MAFLD
变量 | 模型1 | 模型2 | 模型3 | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
β | SE | Wald χ2值 | OR(95%CI) | P值 | β | SE | Wald χ2值 | OR(95%CI) | P值 | β | SE | Wald χ2值 | OR(95%CI) | P值 | |
eGDR | -0.247 | 0.033 | 54.322 | 0.781(0.732,0.834) | <0.001 | -0.244 | 0.032 | 60.129 | 0.783(0.736,0.833) | <0.001 | -0.206 | 0.027 | 59.131 | 0.814(0.772,0.858) | <0.001 |
eGDR分组(以T3组为参照) | |||||||||||||||
T1组 | 0.351 | 0.158 | 4.957 | 1.420(1.043,1.934) | 0.026 | 0.381 | 0.151 | 6.328 | 1.464(1.088,1.969) | 0.012 | 0.270 | 0.136 | 3.916 | 1.31(1.003,1.712) | 0.048 |
T2组 | 1.076 | 0.169 | 40.448 | 2.934(2.106,4.089) | <0.001 | 1.090 | 0.160 | 46.324 | 2.973(2.172,4.068) | <0.001 | 0.938 | 0.14 | 44.935 | 2.554(1.941,3.359) | <0.001 |
变量 | β | SE | Wald χ2值 | OR(95%CI) | P值 |
---|---|---|---|---|---|
性别 | |||||
男性 | 1.000 | 0.220 | 20.740 | 2.719(1.768,4.183) | <0.001 |
女性 | 1.168 | 0.281 | 17.246 | 3.215(1.853,5.580) | <0.001 |
年龄 | |||||
>65岁 | 1.140 | 0.322 | 12.496 | 3.125(1.662,5.879) | <0.001 |
≤65岁 | 1.065 | 0.206 | 26.850 | 2.900(1.939,4.339) | <0.001 |
HbA1c | |||||
≤9% | 1.168 | 0.254 | 21.089 | 3.108(1.896,5.094) | <0.001 |
>9% | 1.297 | 0.284 | 20.814 | 3.657(2.095,6.383) | <0.001 |
BMI | |||||
≤24 kg/m2 | 0.744 | 0.444 | 2.809 | 2.104(0.882,5.024) | 0.904 |
>24 kg/m2 | 0.688 | 0.204 | 11.315 | 1.989(1.332,2.969) | 0.001 |
GGT | |||||
≤31.5 U/L | 0.886 | 0.209 | 17.934 | 2.427(1.610,3.658) | <0.001 |
>31.5 U/L | 1.309 | 0.319 | 16.806 | 3.702(1.980,6.921) | <0.001 |
高血压 | |||||
有 | 2.252 | 0.671 | 11.251 | 9.509(2.550,35.455) | 0.001 |
无 | 0.729 | 0.442 | 2.718 | 2.073(0.871,4.933) | 0.099 |
Table 6 Subgroup analysis of eGDR and MAFLD with T2DM
变量 | β | SE | Wald χ2值 | OR(95%CI) | P值 |
---|---|---|---|---|---|
性别 | |||||
男性 | 1.000 | 0.220 | 20.740 | 2.719(1.768,4.183) | <0.001 |
女性 | 1.168 | 0.281 | 17.246 | 3.215(1.853,5.580) | <0.001 |
年龄 | |||||
>65岁 | 1.140 | 0.322 | 12.496 | 3.125(1.662,5.879) | <0.001 |
≤65岁 | 1.065 | 0.206 | 26.850 | 2.900(1.939,4.339) | <0.001 |
HbA1c | |||||
≤9% | 1.168 | 0.254 | 21.089 | 3.108(1.896,5.094) | <0.001 |
>9% | 1.297 | 0.284 | 20.814 | 3.657(2.095,6.383) | <0.001 |
BMI | |||||
≤24 kg/m2 | 0.744 | 0.444 | 2.809 | 2.104(0.882,5.024) | 0.904 |
>24 kg/m2 | 0.688 | 0.204 | 11.315 | 1.989(1.332,2.969) | 0.001 |
GGT | |||||
≤31.5 U/L | 0.886 | 0.209 | 17.934 | 2.427(1.610,3.658) | <0.001 |
>31.5 U/L | 1.309 | 0.319 | 16.806 | 3.702(1.980,6.921) | <0.001 |
高血压 | |||||
有 | 2.252 | 0.671 | 11.251 | 9.509(2.550,35.455) | 0.001 |
无 | 0.729 | 0.442 | 2.718 | 2.073(0.871,4.933) | 0.099 |
项目 | 最佳截断值 | AUC(95%CI) | 灵敏度(%) | 特异度(%) |
---|---|---|---|---|
FBG | 8.495 mmol/L | 0.550(0.520,0.581) | 52.5 | 57.2 |
联合预测模型 | 0.559 | 0.743(0.715,0.771) | 59.3 | 77.3 |
HbA1c | 7.750% | 0.530(0.499,0.561) | 71.2 | 38.9 |
Table 7 Predictive value of combined prediction model,FBG and HbA1c for MAFLD in T2DM
项目 | 最佳截断值 | AUC(95%CI) | 灵敏度(%) | 特异度(%) |
---|---|---|---|---|
FBG | 8.495 mmol/L | 0.550(0.520,0.581) | 52.5 | 57.2 |
联合预测模型 | 0.559 | 0.743(0.715,0.771) | 59.3 | 77.3 |
HbA1c | 7.750% | 0.530(0.499,0.561) | 71.2 | 38.9 |
[1] |
|
[2] |
|
[3] |
|
[4] |
|
[5] |
|
[6] |
|
[7] |
|
[8] |
|
[9] |
|
[10] |
|
[11] |
|
[12] |
|
[13] |
|
[14] |
中华医学会肝病学分会脂肪肝和酒精性肝病学组. 非酒精性脂肪性肝病诊疗指南(2010年修订版)[J]. 中华肝脏病杂志. 2010,18(3):163-166. DOI:10.3760/cma.j.issn.1007-3418.2010.03.002.
|
[15] |
|
[16] |
|
[17] |
|
[18] |
|
[1] | BAI Haiwei, MI Xiaokun, LIU Qingrui, ZHU Lin, WANG Yingnan, LIU Junyan, HAN Ying. Predictive Value of Serum Uric Acid in Perioperative Acute Ischemic Stroke in Patients with Non-small Cell Lung Cancer [J]. Chinese General Practice, 2023, 26(36): 4545-4551. |
[2] | CHU Xiaojing, LI Jun, FU Yanqin, LIU Danqing, LIU Aiping, ZHANG Yuanyuan. Effect of Human Body Composition and Serum Biochemical Indicators on the Accuracy of Flash Glucose Monitoring System [J]. Chinese General Practice, 2023, 26(35): 4433-4438. |
[3] | LUO Weigang, YIN Yuanyuan, LIU Wanhu, XU Yuzhu, CAO Xiaoyun, BU Wei, ZHANG Lingyan, REN Huiling. Correlation of Triglyceride Glucose Index with Early Neurological Deterioration in Patients with Single Subcortical Infarction [J]. Chinese General Practice, 2023, 26(35): 4419-4424. |
[4] | XIE Xuemei, GAO Jing, BAI Dingxi, LU Xianying, HE Jiali, LI Yue. Current Status of Polypharmacy in the Elderly and Its Influencing Factors: a Meta-analysis [J]. Chinese General Practice, 2023, 26(35): 4394-4403. |
[5] | WANG Yue, CHEN Qing, LIU Lurong. Detection Rate of Depression and Its Influencing Factors in Chinese Elderly: a Meta-analysis [J]. Chinese General Practice, 2023, 26(34): 4329-4335. |
[6] | LI Dianjiang, PAN Enchun, SUN Zhongming, WEN Jinbo, WANG Miaomiao, WU Ming, SHEN Chong. The Current Status and Influencing Factors of Clinical Inertia in Type 2 Diabetes Patients in Community [J]. Chinese General Practice, 2023, 26(34): 4296-4301. |
[7] | HAO Aihua, ZENG Weilin, LI Guanhai, XIA Yinghua, CHEN Liang. Current Situation of the Construction of Family Doctor Team: an Investigation Based on the Perspective of General Practitioners [J]. Chinese General Practice, 2023, 26(34): 4261-4268. |
[8] | QIN Fengyin, ZHANG Qishan, LAI Jinjia, HUANG Yimin, HAN Guoyin, SUN Xinglan, WANG Fen, TAN Yibing. Current Status and Influencing Factors of the Intention to Screen for High-risk Stroke among Community Residents in Guangdong [J]. Chinese General Practice, 2023, 26(34): 4283-4289. |
[9] | ZHANG Jin, DING Zhiguo, QI Shuo, LI Ying, LI Weiqiang, ZHANG Yuanyuan, ZHOU Tong. Relationship between Serum Thyroid Hormone Levels and Prognosis during Hospitalization in Heart Failure Patients [J]. Chinese General Practice, 2023, 26(33): 4125-4129. |
[10] | ZHOU Yuyu, GAO Chuan, CUI Puan, WANG Yaping, HE Zhong. Influencing Factors of Shared Decision Making between Doctors and Patients in Menopausal Hormone Therapy in Patients with Menopausal Syndrome [J]. Chinese General Practice, 2023, 26(33): 4181-4186. |
[11] | WANG Lina, GAO Pengfei, CAO Fan, GE Ying, YAN Wei, HE Daikun. Analysis of the Prevalence and Influencing Factors of Non-alcoholic Fatty Liver Disease in Different Gender Groups [J]. Chinese General Practice, 2023, 26(33): 4143-4151. |
[12] | LIANG Xuan, NA Feiyang, QIN Mengyao, YANG Hui, GUO Li, GUO Qi, REN Lei, CHEN De, LIU Donghai, ZHANG Rongfang. Clinical Characteristics and Influencing Factors of Bronchial Asthma Combined with Obstructive Sleep Apnea-hypopnea Syndrome in Children [J]. Chinese General Practice, 2023, 26(33): 4225-4230. |
[13] | LI Qianqian, CHEN Xunrui, ZHANG Wenying, YUAN Haihua, ZHANG Yanjie, JIANG Bin, LIU Feng. Demand and Influencing Factors for Community Health Services during Chemotherapy of Patients with Advanced Cancer [J]. Chinese General Practice, 2023, 26(33): 4173-4180. |
[14] | GAO Dekang, WEI Shaohua, MA Xiaoming, DU Peng, XING Chungen, CAO Chun. Risk Factors for Loss of Skeletal Muscle Mass and Its Correlation with Complications after Major Hepatectomy for Liver Cancer [J]. Chinese General Practice, 2023, 26(32): 4031-4037. |
[15] | WANG Minghuan, LI Yuhong, YU Min, WANG Yougang, YU Qiaozhi, YANG Fangfang, YUAN Dehui, ZHANG Liu. Effect of Allostatic Load on Adverse Pregnancy Outcomes of Women in Late Pregnancy [J]. Chinese General Practice, 2023, 26(32): 4064-4069. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||